VPB0617 - Increased CD62P Platelet Expression in Deceased COVID-19 Patients

Background: There is an association between Coronavirus Disease 2019 (COVID-19) and coagulation abnormalities. Platelet monitoring is important for COVID-19 because abnormalities can occur in terms of quantity and quality. Impaired function of platelets can occur at the activation or aggregation stages. An increase in CD62P is associated with a 1.7-fold increased risk of venous thrombosis. In the event of thrombosis, platelet activation causes interactions between fibrinogen and GP IIb/IIIa molecules which will form intracellular bonds between platelets, causing platelet aggregation. This suggests the role of CD62P as a major marker of platelet activation and may mediate cancer cell adhesion, inflammation, and thrombosis

Aims: This study aims to determine the description of platelet function as reflected in CD62P platelet expression in COVID-19 patients

Methods: This study is a prospective study that take place from November 2020 to September 2021 at RSUP Dr. Sardjito, Yogyakarta, Indonesia. The subjects involved were adult patients aged over 18 years, men and women with confirmed COVID-19 through PCR swab results. Patients with leukemia, history of coagulation disease, and immunodeficiency were excluded from this study. Flowcytometry analysis using FACS Canto was used to measure CD62P expression on platelets. Antibody used was anti human monoclonal CD41 PE and CD62P FITC antibody. The CD62P examination was carried out on the first day of treatment. Patients were grouped according to the severity of COVID-19 as severe and non-severe. Mann Whitney test was used to compare CD62P platelet expression percentage between groups.

Results: The CD62P platelet expression on day 1 of the deceased subjects were higher compared to the survived subjects (46.77% vs 43.38%; p=0.04). On day 1, the severe subjects have a higher mean CD62P platelet expression compared to non-severe subjects (47.88 % vs 39.75%).

Conclusion(s): CD62P platelet expression in deceased COVID-19 subjects is higher compared to survived subjects.